Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386

1.
2.

Candesartan cilexetil and renal hemodynamics in hypertensive patients.

Fridman K, Wysocki M, Friberg P, Andersson OK.

Am J Hypertens. 2000 Sep;13(9):1045-8.

PMID:
10981559
3.

Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.

Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.

Eur J Clin Pharmacol. 1998 Sep;54(7):497-501.

PMID:
9832289
4.
6.

Pharmacokinetic-pharmacodynamic interactions of candesartan cilexetil and losartan.

Azizi M, Chatellier G, Guyene TT, Ménard J.

J Hypertens. 1999 Apr;17(4):561-8.

PMID:
10404959
8.

Candesartan cilexetil protects against loss of autoregulatory efficiency in angiotensin II-infused rats.

Inscho EW, Imig JD, Deichmann PC, Cook AK.

J Am Soc Nephrol. 1999 Jan;10 Suppl 11:S178-83.

PMID:
9892160
9.
10.
11.
13.

Elevated arterial pressure impairs autoregulation independently of AT(1) receptor activation.

Inscho EW, Cook AK, Murzynowski JB, Imig JD.

J Hypertens. 2004 Apr;22(4):811-8.

PMID:
15126924
14.

[Angiotensin-II receptor inhibitors in hemodialysed uremia patients with arterial hypertension: candesartan cilexitil versus losartan].

Cice G, Ferrara L, Tagliamonte E, Russo PE, Di Benedetto A, Iacono A.

Cardiologia. 1999 Dec;44(12):1071-6. Italian.

PMID:
10687258
15.

Dose-dependent blockade of the angiotensin II type 1 receptor with losartan in normal volunteers.

Berlowitz MS, Latif F, Hankins SR, Ennezat PV, Moskowitz R, Tandon S, Colombo PC, Le Jemtel TH.

J Cardiovasc Pharmacol. 2001 Jun;37(6):692-6.

PMID:
11392465
16.

Renal effects of angiotensin I-receptor blockade and angiotensin convertase inhibition in man.

Schmitt F, Natov S, Martinez F, Lacour B, Hannedouche TP.

Clin Sci (Lond). 1996 Mar;90(3):205-13.

PMID:
8777826
18.

Differences in AT2 -receptor stimulation between AT1 -receptor blockers valsartan and losartan quantified by renal interstitial fluid cGMP.

Siragy HM, El-Kersh MA, De Gasparo M, Webb RL, Carey RM.

J Hypertens. 2002 Jun;20(6):1157-63.

PMID:
12023686
19.

Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.

Pool JL, Glazer R, Chiang YT, Gatlin M.

J Hum Hypertens. 1999 Apr;13(4):275-81.

PMID:
10333347
20.

Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.

Maillard MP, Würzner G, Nussberger J, Centeno C, Burnier M, Brunner HR.

Clin Pharmacol Ther. 2002 Jan;71(1):68-76.

PMID:
11823759

Supplemental Content

Support Center